Idiopathic pulmonary fibrosis (IPF)
IPF is a severe life threatening lung disease characterized by a progressive and irreversible decline in lung function. The median life expectancy is 3-4 years, and although current medicines partially slow the disease, a high unmet medical need remains for safe and well-tolerated medicines that can halt, and potentially reverse, it’s progression. Galecto is developing an inhaled galectin-3 inhibitor – TD-139. In a phaseIb/IIa trial in IPF, TD139 was safe and well tolerated, and demonstrated unprecedented effects on important biomarkers of disease activity.